Monopar Therapeutics Inc

Monopar Therapeutics Inc is not a good value stock. Monopar Therapeutics Inc is a mediocre stock to choose.

News

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

Globe Newswire WILMETTE, Ill., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients...\n more…

HC Wainwright Increases Monopar Therapeutics (NASDAQ:MNPR) Price Target to $6.00

Ticker Report Monopar Therapeutics (NASDAQ:MNPR - Free Report) had its target price increased by HC Wainwright from $2.00 to $6.00 in a research report released on Wednesday morning, Benzinga reports. The...\n more…

Monopar Therapeutics target adjusted to $9 from $2 at JonesResearch

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Buy Rating Affirmed for Monopar Therapeutics on Clinical Progress and Strategic Financial Positioning

TipRanks Financial Blog In a report released today, Justin Walsh from JonesTrading reiterated a Buy rating on Monopar Therapeutics Inc (MNPR - Research Report), with a pri...\n more…

Monopar Therapeutics Inc. Forecasted to Earn Q3 2024 Earnings of ($2.60) Per Share (NASDAQ:MNPR)

Zolmax Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2024 earnings estimates for Monopar Therapeutics in a report issued on Monday...\n more…

Analysts Set Expectations for Monopar Therapeutics Inc.'s Q1 2025 Earnings (NASDAQ:MNPR)

Zolmax Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Monopar Therapeutics in a research...\n more…